Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124765903 | 12476590 | 3 | F | 20160701 | 20160617 | 20160712 | EXP | US-ELI_LILLY_AND_COMPANY-US201606004892 | ELI LILLY AND CO | 59.00 | YR | F | Y | 173.24000 | KG | 20160712 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124765903 | 12476590 | 1 | PS | ADCIRCA | TADALAFIL | 1 | Unknown | UNK, UNKNOWN | U | U | 21368 | 40 | MG | TABLET | |||||
| 124765903 | 12476590 | 2 | SS | AMBRISENTAN | AMBRISENTAN | 1 | Unknown | 10 MG, QD | 1504767A | 0 | 10 | MG | QD | ||||||
| 124765903 | 12476590 | 3 | SS | REMODULIN | TREPROSTINIL | 1 | Intravenous (not otherwise specified) | 0.029 UG/KG | U | U | 926618 | 0 | |||||||
| 124765903 | 12476590 | 4 | SS | REMODULIN | TREPROSTINIL | 1 | Intravenous (not otherwise specified) | 2.5 MG, UNKNOWN | U | U | 0 | 2.5 | MG | ||||||
| 124765903 | 12476590 | 5 | C | ELIQUIS | APIXABAN | 1 | 0 | ||||||||||||
| 124765903 | 12476590 | 6 | C | HUMIRA | ADALIMUMAB | 1 | 0 | ||||||||||||
| 124765903 | 12476590 | 7 | C | VOLTAREN | DICLOFENAC SODIUM | 1 | 0 | ||||||||||||
| 124765903 | 12476590 | 8 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 0 | ||||||||||||
| 124765903 | 12476590 | 9 | C | CYCLOBENZAPRINE | CYCLOBENZAPRINE | 1 | 0 | ||||||||||||
| 124765903 | 12476590 | 10 | C | ZOLPIDEM | ZOLPIDEMOLPIDEM TARTRATE | 1 | 0 | ||||||||||||
| 124765903 | 12476590 | 11 | C | ATROVENT | IPRATROPIUM BROMIDE | 1 | 0 | ||||||||||||
| 124765903 | 12476590 | 12 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | 0 | ||||||||||||
| 124765903 | 12476590 | 13 | C | MECLIZINE | MECLIZINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 124765903 | 12476590 | 14 | C | TOPAMAX | TOPIRAMATE | 1 | 0 | ||||||||||||
| 124765903 | 12476590 | 15 | C | POTASSIUM | POTASSIUM | 1 | 0 | ||||||||||||
| 124765903 | 12476590 | 16 | C | BENADRYL | DIPHENHYDRAMINE HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124765903 | 12476590 | 1 | Product used for unknown indication |
| 124765903 | 12476590 | 2 | Pulmonary hypertension |
| 124765903 | 12476590 | 3 | Pulmonary arterial hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124765903 | 12476590 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124765903 | 12476590 | Chest pain | |
| 124765903 | 12476590 | Dyspnoea | |
| 124765903 | 12476590 | Hyperkalaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124765903 | 12476590 | 2 | 20131011 | 0 | ||
| 124765903 | 12476590 | 3 | 20150523 | 0 |